Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD oral solution safety, tolerability, pharmacokinetics, and food-effect study in healthy volunteers
NL-OMON42686Active, not recruiting
- Sponsor
- GW Pharmaceuticals
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of cannabidiol in epilepsy (5 arms), sponsored by GW Pharmaceuticals. Primary endpoints: Safety and tolerability, Vital signs and 3 more. Started May 2015; status: active, not recruiting.
02
Drugs
cannabidiol
03
Conditions
epilepsy
Beyond the preview
Go deeper on NL-OMON42686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42686.